Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Emily Turner

Clinical Nurse Specialist, Adult Health Lowell, AR Nurse Practitioner

NPI 1013329218 CMS profile 10912573

325 S 6Th Pl, Lowell, AR 72745

Open in the dashboard

General payments

$1,915

107 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emily Turner of Lowell, AR is reported in the CMS Open Payments database as having received $1,915 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $707 45
2024 General $552 35
2023 General $597 24
2022 General $60 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emily Turner
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Emily Turner were reported at $707. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Emily Turner Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $133 $48–$445 $132
2022 $60 $163 $57–$526 $149
2023 $597 $173 $64–$597 $160
2024 $552 $171 $54–$575 $164
2025 $707 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novartis Pharmaceuticals Corporation $341 24 payments
  2. Amgen Inc. $213 17 payments
  3. Merck Sharp & Dohme Corporation $192 11 payments
  4. AstraZeneca Pharmaceuticals LP $185 5 payments
  5. Pfizer Inc. $150 9 payments
  6. E.R. Squibb & Sons, L.L.C. $110 7 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $93 1 payment
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $86 5 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $82 4 payments
  10. Novo Nordisk Inc $80 4 payments
  11. Other $383 20 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,915 107 payments
Products named General payments · program years 2022–2025
  1. LEQVIO $299 21 payments
  2. VERQUVO $263 15 payments
  3. ENTRESTO $178 11 payments
  4. REPATHA $139 12 payments
  5. IMFINZI $113 1 payment
  6. NURTEC ODT $97 6 payments
  7. ELIQUIS $97 6 payments
  8. LifeVest $93 1 payment
  9. Kerendia $82 4 payments
  10. CAMZYOS $80 5 payments
  11. Other $1,023 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

2,106

Median for Nurse Practitioner: 389

Drug cost

$364,907

Median for Nurse Practitioner: $21,885

Branded share of claims

24.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 143 $156,512
Xarelto Rivaroxaban Brand 72 $79,576
Entresto Sacubitril/Valsartan Brand 41 $57,186
Jardiance Empagliflozin Brand 32 $30,931
Repatha Sureclick Evolocumab Brand 43 $25,190
Metoprolol Succinate Generic 359 $2,494
Atorvastatin Calcium Generic 240 $1,897
Chlorthalidone Generic 59 $1,125
Flecainide Acetate Generic 26 $914
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 34 $815

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$17,965

Medicare's payments for the services billed

Medicare patients

266

Average age 74

Services billed

340

129 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 67%
Arthritis 45%
Diabetes 29%
Atrial fibrillation 28%
Chronic kidney disease 28%
Heart failure 22%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $139
$139 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $71
$71 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $60
$60 72 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $56
$56 41 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $53
$53 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record